Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
OpenAI Hires OpenClaw Creator Peter Steinberger to Advance Next-Generation AI Agents 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Warner Bros. Discovery Weighs Renewed Sale Talks With Paramount Skydance Amid Netflix Deal Review 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Freedom Finance and Binance Join Forces in Digital Assets 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
EAST RUTHERFORD, N.J., April 26, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the market opens.
The Company will host a conference call to discuss the financial results.
| First Quarter 2018 Earnings Conference Call | |
| When: | Thursday, May 3, 2018 at 8:30 a.m. Eastern Time |
| Dial-in: | 1-877-260-1479 for U.S. |
| 1-334-323-0522 for International | |
| Passcode: 5093025 | |
| Dial-in Replay: | 1-888-203-1112 for U.S. |
| 1-719-457-0820 for International | |
| Passcode: 5093025 | |
| Available through Thursday, May 10, 2018 | |
| Webcast: | www.cambrex.com |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing. For more information, please visit www.cambrex.com.
| Contact: | Stephanie LaFiura |
| Investor Relations Associate | |
| Tel: 201-804-3037 | |
| Email: [email protected] |
